On May 25, 2023, Camac Partners, LLC filed a preliminary proxy statement soliciting proxies and recommending the shareholders of Forte Biosciences, Inc. to vote for the election of its 2 nominees, Michael G. Hacke and Chris McIntyre, and not to vote for the 2 Company nominees, Lawrence Eichenfield and Paul A. Wagner, at the Company?s 2023 annual shareholders meeting.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.651 USD | +3.33% | -12.62% | -20.77% |
May. 13 | Tocagen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Mar. 18 | Forte Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-20.77% | 22.93M | |
+8.87% | 114B | |
+11.47% | 104B | |
-12.65% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-3.12% | 17.89B | |
+8.33% | 14.28B | |
+34.99% | 12.55B |
- Stock Market
- Equities
- FBRX Stock
- News Forte Biosciences, Inc.
- Camac Partners Solicits Proxies from Shareholders of Forte Biosciences